Evidence map›Paper›PMID 41321442›Full record

ArticleMedical cannabis and cannabinoids

Cannabis Use in Central Disorders of Hypersomnolence in the Netherlands.

Marieke Vringer, Michel Cronie, Aniek Remmerswaal, Linda E Klumpers, Gert Jan Lammers, Rolf Fronczek, Mink S Schinkelshoek

Abstract read
In one paragraph

Article in Medical cannabis and cannabinoids. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marieke VringerDepartment of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
Michel CronieDepartment of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
Aniek RemmerswaalSleep-Wake Centre, Heemstede, The Netherlands.
Linda E KlumpersTomori Pharmacology Inc., Denver, CO, USA.
Gert Jan LammersDepartment of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
Rolf FronczekDepartment of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
Mink S SchinkelshoekDepartment of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The endocannabinoid system plays a role in sleep-wake regulation. In clinical practice, people with central disorders of hypersomnolence (CDH) frequently report use of cannabis. Methods: We compared lifetime and current use of cannabis of people with CDH to the Dutch general population. Additionally, we assessed cannabis use in relation to hypersomnolence symptoms. Results: In total, 76 (out of 88) patients completed the online questionnaire. Lifetime cannabis use (42% vs. 23%, Conclusion: This study provides a rationale for future research on the potential benefits of cannabis in CDH.

Indexed as

CannabidiolCannabisHypersomnolenceIdiopathic hypersomniaNarcolepsyTetrahydrocannabinol

Identifiers

PMID41321442
PMCPMC12659163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.